Search results for Arrowhead Pharmaceuticals

Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J

Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with metabolic dysfunction-associated steato...

Form 144 Arrowhead Pharmaceuticals Inc. For: 23 April

Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH

Madrigal Pharmaceuticals has licensed rights to an Arrowhead Pharmaceuticals small-interfering RNA therapy designed to address a particular genetic mutation associated with the fat...

<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>

Apogee eczema drugs gets Blackstone backing, heads to Phase 3

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.

Aspire Biopharma Issues Shareholder Letter

Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Hu-mAtrIxâ„¢-Enabled Next-Generation ACVR2A/2B-

A migraine drugmaker heads to the public markets through reverse merger

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing...

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AAC...

Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Aardvark to dig into phase 3 data early after FDA imposes hold

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome program after the FDA put a full clinical hold on its studies.

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antit...

<![CDATA[Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-P...

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

<![CDATA[FDA Places Full Clinical Hold on Aardvark Therapeutics’ ARD-101]]>

Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential

Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst

Revolution Medicines

Revolution Medicines Anonymous (not verified) Tue, 05/05/2026 - 02:20 field_thread_url https://cafepharma.com/boards/threads/revolution-medicines.709803/...

Apogee Therapeutics: Targeting Atopic Dermatitis

Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune...

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substanti...

Program Enters Final Stage of Dose OptimizationData Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

FDA hold puts Aardvark Prader-Willi drug in limbo

The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.